Gulf HTA & Africa RWE

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: Gulf Cooperation Council HTA developments, Brazilian pricing reforms, African RWE integration, Australian digital therapeutics, and Japan's gene therapy evidence strategies. Let's get into it.

MarcusFirst, HTA in the Gulf Cooperation Council. HTA bodies are increasingly adopting structured frameworks for orphan drugs. Saudi Arabia and UAE have launched parallel review programs with unified clinical assessment timelines. But the evidence standards remain fragmented. Sara, how are commercial teams adapting to these divergent approaches?

SaraThe Gulf's unified review is a myth. Each country retains distinct reimbursement thresholds and utility weights. Commercial teams are forced to develop bespoke evidence packages. The UAE's focus on cost-per-QALY contrasts with Saudi Arabia's budget impact thresholds. Marcus, isn't this just creating administrative duplication without actual harmonization?

MarcusAdministrative burden is the price of regional alignment. The unified clinical assessment reduces duplication in data submission. The alternative—separate dossiers for each Gulf state—is unsustainable. The evidence requirements are converging, even if reimbursement criteria lag.

SaraConvergence is aspirational. Until the Gulf states agree on cost-effectiveness thresholds, we'll see inconsistent outcomes. The UAE's acceptance of real-world evidence contrasts with Saudi Arabia's preference for RCTs. That's not convergence—it's chaos for evidence strategy.

MarcusMoving to Brazilian pricing policy reforms. Brazil has expanded its reference pricing system to include biologics. The ANVISA now requires comparative effectiveness data for all new submissions. But the price negotiation timeline has extended to 18 months. Sara, what's the commercial impact of these expanded reference pools?

SaraBrazil's reference pricing is becoming a regional benchmark. The inclusion of biosimilars in reference pools forces originators to justify premium pricing. But the 18-month negotiation window creates massive cash flow disruption. Marcus, isn't this just a mechanism to delay reimbursement without improving evidence quality?

MarcusDelay is inevitable in resource-constrained systems. The extended timeline allows for more rigorous HTA assessment. Brazil's focus on comparative effectiveness is raising the evidence bar. The alternative—rapid approvals without robust data—undermines sustainability.

SaraSustainability requires timely access. The evidence bar is rising while reimbursement timelines are lengthening. That's a contradiction. Brazil's system is becoming a bottleneck, not a model.

MarcusRWE integration in Africa. African HTA bodies are increasingly accepting RWE for submissions, particularly for infectious diseases. Nigeria and Kenya have launched pilot programs for malaria and HIV. But data infrastructure remains a barrier. Sara, how are companies overcoming these data gaps?

SaraCompanies are partnering with local health ministries to leverage national health databases. The RWE is being used for subgroup analyses in HIV. Marcus, isn't this RWE of questionable quality given the heterogeneity in African healthcare systems?

MarcusQuality is context-dependent. African HTA bodies are developing tailored validation frameworks for RWE. The focus is on fit-for-purpose evidence, not Western standards. The alternative—rejecting RWE entirely—leaves critical evidence gaps.

SaraValidation frameworks are still evolving. Until we have standardized RWE methodologies for Africa, submissions will face inconsistent scrutiny. The current approach is experimental, not evidence-based.

MarcusDigital therapeutics in Australia. The PBAC has published updated guidelines for app-based submissions. Digital therapeutics must now demonstrate clinical utility through real-world data. But the reimbursement pathway remains unclear. Sara, what's the commercial strategy for these products?

SaraCompanies are positioning digital therapeutics as complements to traditional drugs. The PBAC's focus on clinical utility is forcing developers to prove real-world impact. Marcus, isn't this just creating an impossible evidence burden for novel modalities?

MarcusThe burden is appropriate. Digital therapeutics must demonstrate comparable efficacy to established treatments. The PBAC's guidelines are raising the bar for evidence quality. The alternative—lower standards—would undermine the HTA process.

SaraThe bar is being raised without clear pathways. Until the PBAC defines how digital endpoints will be valued, commercial planning is guesswork. The guidelines are creating more questions than answers.

MarcusGene therapy HEOR in Japan. Japan's PMDA has expanded its regenerative medicine framework to include gene therapies. Evidence requirements now include long-term follow-up data. But the cost-effectiveness threshold remains undefined. Sara, how are companies justifying premium pricing without clear benchmarks?

SaraCompanies are emphasizing unmet need and budget impact. Japan's system values innovation regardless of cost-effectiveness. Marcus, isn't this a return to pre-HTA pricing logic with no accountability for value?

MarcusValue is multidimensional. Japan's system recognizes that traditional QALY metrics don't capture gene therapy benefits. The expanded evidence requirements ensure rigorous assessment. The alternative—applying standard cost-effectiveness thresholds—would stifle innovation.

SaraInnovation without value assessment is unsustainable. Japan's approach risks creating high-cost, low-evidence products. The long-term follow-up data requirement is a step forward, but without cost-effectiveness, it's incomplete.

MarcusSara makes valid points on evidence gaps, but regional frameworks are evolving. The Gulf's harmonization efforts, while imperfect, reduce duplication. Brazil's reference pricing expands access despite delays. Africa's RWE adoption bridges critical data shortages. Australia's digital guidelines force clinical utility. Japan's gene therapy framework prioritizes innovation. The tension between evidence rigor and access remains unresolved.

SaraThe unresolved tension is the core issue. Without unified value frameworks, HEOR teams are navigating moving targets. Regional variations are creating administrative burdens, not evidence-based systems. The focus must shift toward harmonization, not just incremental adjustments.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.